TAM
LGND icon

Tucker Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Tucker Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2
Closed -$120 – 1517
2023
Q3 		$120 Hold
2
– – ﹤0.01% 1318
2023
Q2 		$144 Hold
2
– – ﹤0.01% 1093
2023
Q1 		$147 Hold
2
– – ﹤0.01% 1111
2022
Q4 		$135 Sell
2
-1
-33% -$65 ﹤0.01% 772
2022
Q3 		$175 Buy
+3
New +$176 ﹤0.01% 801

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tucker Asset Management's LGND Position: Q4 2023 in Review

Tucker Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2023, closing a stake of 2 shares — an estimated $120 sold.

Tucker Asset Management first reported a position in LGND in Q3 2022 and held it in 5 quarters. The position peaked at $175 in Q3 2022. 211 funds tracked by Wall St. Rank hold LGND as of Q4 2023.

  • Tucker Asset Management reported no remaining Ligand Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Tucker Asset Management sold 2 Ligand Pharmaceuticals shares in Q4 2023, an estimated $120.
  • Tucker Asset Management first reported a position in Ligand Pharmaceuticals in Q3 2022 and held it in 5 quarters.
  • Tucker Asset Management's Ligand Pharmaceuticals position peaked at $175 in Q3 2022.
  • 211 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2023.

Based on Tucker Asset Management's 13F filing for Q4 2023, filed 4 Mar 2024.